News

MOR106 was jointly discovered by MorphoSys and Galapagos under their collaboration, and has a novel mode of action with potential application in inflammation. The primary objective of the

The IND is now active. This will be Adaptimmune’s second wholly-owned therapeutic candidate to enter clinical trials. The company initiated a study in December 2015 to evaluate its

The CHMP also noted that the importance of favourable effects of RUCONEST is further supported by the continued availability of supply of RUCONEST (produced by recombinant technology) in

The target date for the FDA to take action under the Prescription Drug User Fee Act is 29 May. If approved by FDA, the drug would be the

The approval expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies. Two formulations have been approved

The randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, phyarmacodynamics, and glucose and insulin dose-lowering properties of REMD-477 in up to 20 patients with type 1 diabetes

These agreements relate to Eisai’s global oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as the Company’s global epilepsy therapy, Fycompa (perampanel). Under the proposed agreements, important

Additionally, Incyte has amended its Collaboration and License Agreement with Novartis, granting Novartis exclusive research, development and commercialization rights for ruxolitinib in GVHD outside the U.S. "We are

Lumos will use the proceeds for clinical trials and commercialization of its lead compound, LUM-001, for the treatment of Creatine Transporter Deficiency (CTD). Funding will also be used